Petitioners Ask To Add 3 Ailments To Medical Marijuana Program - Hartford Courant

Healthiest Foods of All Time (With Recipes)





State law currently allows residents 18 or older to register as medical marijuana patients if they have any of the following conditions: cancer, glaucoma, HIV or AIDS, Parkinson's disease, multiple sclerosis, intractable spasticity related to nerve damage in the spinal cord, epilepsy, cachexia, wasting syndrome, Crohn's disease or post-traumatic stress disorder. This is the second wave of petitions to expand the medical marijuana program. Several other conditions could be added soon: sickle cell disease; severe psoriasis and psoriatic arthritis; and post-laminectomy syndrome with chronic radiculopathy recurring back pain after surgery. Petitioners asked for those conditions to be added. The state medical marijuana program's board of physicians reviewed them and recommended they be added to the list of existing conditions. The board of physicians declined to add Tourette syndrome. The marijuana program is part of the state Department of Consumer Protection, overseen by Commissioner Jonathan A. Harris. For the original version including any supplementary images or video, visit http://www.courant.com/business/hc-medical-marijuana-connecticut-colitis-20150302-story.html?track=rss





Research and Markets: Chronic Plaque Psoriasis Pipeline Review 2015 - Analysis of 20 Companies & 22 Drug Profiles - Yahoo Finance





And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark . Todd Campbell has no position in any stocks mentioned. For the original version including any supplementary images or video, visit http://www.investopedia.com/articles/markets/030215/amgens-next-big-thing.asp?partner=mediafed





Is This Amgen's Next Big Thing? (AMGN)





Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com . Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cellceutix-expand-skin-product-pipeline-143141096.html





Cellceutix to Expand Its Skin Product Pipeline - Yahoo Finance





This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new palmar pustular psoriasis targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development AbGenomics International, Inc. For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/research-markets-chronic-plaque-psoriasis-121800165.html









Skin can become dull, patchy, spotted and wrinkled, and while you might be tempted to go for a fancy face cream, what you eat may bring more potent results. How? Omega-3s in foods like salmon may http://psoriasiscureblog.info/sitemap help reduce dryness (from atopic dermatitis and psoriasis) and may even reduce the risk of skin cancer. Serving size: 3 oz, cooked Nutrition per serving: 1/2 teaspoon grated orange rind 1 garlic clove, crushed 4 (6-ounce) salmon fillets (about 1 inch thick) 8 ounces uncooked angel hair pasta Cooking spray Lime slices (optional) Preparation Combine first 8 ingredients in a large zip-top plastic bag; add fish to bag. For the original version including any supplementary images or video, visit http://time.com/3724505/50-healthiest-foods/